Share
Linkedin
Twitter
Facebook
Whatsapp
Copy Link
Tempus AI shares climbed Wednesday following the launch of its new HRD-RNA algorithm, an AI-driven tool designed to detect homologous recombination deficiency in tumors. The algorithm analyzes gene expression to identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering a more dynamic assessment than traditional genomic methods.
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.